Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
8 V; {6 I# X0 u ]NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 1 k' H4 c+ S" K/ k [
+ Author Affiliations$ }( }' A/ y) b1 b s+ s
6 }/ G3 e, w" P/ r$ E# m1 V2 L5 b
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 0 O& O. |; a" ?2 S8 v
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 9 Z9 s$ b% [* C2 v" V
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3 ~6 E6 m+ C, e$ v4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan / P( f8 ^3 v% n# X
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + i: x1 O5 l) c
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
2 D2 ^+ [1 E: n* k/ y0 O6 F. m7Kinki University School of Medicine, Osaka 589-8511, Japan + X, P) | a" m$ l
8Izumi Municipal Hospital, Osaka 594-0071, Japan
5 r% F0 ?: Z% E1 h' l" L9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 2 G5 |8 a" N' V* a9 S8 `; h' N
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
/ y0 [7 a; z& o8 i0 F7 b: S, ]% GAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
. a5 ~# H/ I) y. J7 m7 ^* [+ H9 W- C- O1 }1 p
|